Erbitux

What Erbitux is used for

Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. For details, see section 5.1. Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer: in combination with encorafenib and FOLFOX for the first line treatment; in combination with encorafenib in patients who have received prior systemic therapy. For details, see section 5.1, for biomarker-based patient selection, see section 4.2. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck: in combination with radiation therapy for locally advanced disease; in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Erbitux

Active substance

cetuximab

Disease area

Head and Neck Neoplasms; Colorectal Neoplasms

Medicine group

Antineoplastic agents

ATC code

L01FE01

Marketing authorisation holder

Merck Europe B.V.

Authorised in the EU since

2004

Official information

• Erbitux: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In the USA

Same active substance: Erbitux

In India

• Cetuximab: 3 brands in India